Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy

Raleigh, David R.; Hsu, I-Chow; Braunstein, Steve; Chang, Albert; Simko, Jeffry P.; Roach, Mack

doi:10.1016/j.brachy.2014.11.008

Cited by 5 publications

(5 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Another atypical region of local prostate cancer recurrence is the bladder wall, distant from the anastomotic area (Fig 10). The posterior bladder wall has a higher risk for tumor relapse because it is near the resection area, despite the idea of surgical seeding being controversial in the literature (36). Both urethral and bladder recurrence may appear as focal or segmental enhancing wall thickening with moderate to high PSMA uptake.…”

Section: Patterns Of Recurrence Local Recurrencementioning

confidence: 99%

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

et al. 2019

View full text Add to dashboard Cite

The introduction of prostate-specific membrane antigen (PSMA) in clinical practice has revolutionized evaluation of biochemical recurrence of prostate cancer after curative-intent treatment. The high expression of this glycoprotein in prostate cancer cells makes PSMA imaging superior to the current conventional staging methods, namely bone scanning and CT. The high capability of PSMA imaging for identifying very small previously undetected lesions has been widely demonstrated in the literature, leading to a rethinking of patient management by oncologists, urologists, and radiation oncologists. The typical and predictable patterns of spread in prostate cancer are still more prevalent, such as spread to pelvic lymph nodes and bone metastasis, but different patterns of disease spread are becoming more commonly recognized with higher reliability because PSMA imaging allows detection of more typical and atypical lesions than conventional imaging. Furthermore, it is important for the reading physician to recognize and understand the typical disease spread and the most prevalent atypical prostate cancer relapses, not only to heighten the relevancy of reports but also to improve imaging consultancy in multispecialty oncologic practice. ©

show abstract

Section: Patterns Of Recurrence Local Recurrencementioning

confidence: 99%

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

et al. 2019

View full text Add to dashboard Cite

show abstract

“…Beyond perineal seeding, there is one reported case in the literature of bladder recurrence of prostate cancer post-brachytherapy presenting with biochemical failure. 6 In this case, review of the CT scan obtained for dosimetry at the time of brachytherapy demonstrated a lone catheter protruding through the bladder wall at the site of eventual recurrence.…”

Section: Discussionmentioning

confidence: 77%

Perineal recurrence of prostate cancer post-brachytherapy

et al. 2019

View full text Add to dashboard Cite

We present a rare case of perineal recurrence of prostate cancer post low dose rate brachytherapy. Increased levels of prostate-specific antigen were recorded 12 years post brachytherapy. Pelvic CT and MRI visualized a nodular lesion in the perineum, and positron emission tomography demonstrated choline-avidity. Ultrasound-guided biopsy of the nodule was performed, yielding histology consistent with prostatic adenocarcinoma. Metastatic prostatic seeding to the perineum is a rare complication of brachytherapy. We discuss the putative mechanism, approach to diagnosis, and management.

show abstract

“…On axial, noncontrast CT ( B ) and PET/CT fusion ( C ) images, the focus corresponded to a poorly defined soft tissue mass (arrows) along the left posterolateral urinary bladder wall. This was suggestive of primary bladder malignancy versus prostate cancer recurrence, the latter being extremely rare at this location 3 . The SUVmax of the lesion was 4.7, which was higher than bone marrow but lower than liver.…”

mentioning

confidence: 76%

“…This was suggestive of primary bladder malignancy versus prostate cancer recurrence, the latter being extremely rare at this location. 3 The SUVmax of the lesion was 4.7, which was higher than bone marrow but lower than liver. There were adjacent additional foci of mild to moderate uptake (arrowheads) (A) that localized to sigmoid colon and were considered physiological.…”

mentioning

confidence: 87%

Papillary Urothelial Carcinoma of Urinary Bladder Identified on 18F-Fluciclovine PET/CT

Meka

Wankhar

Ojili³

et al. 2021

Clin Nucl Med

View full text Add to dashboard Cite

18F-fluciclovine is a radiolabeled synthetic amino acid recently approved by the Food and Drug Administration for evaluating recurrent prostate cancer. Upregulated amino acid transporters in prostate cancer cells result in elevated radiotracer uptake in sites of tumor recurrence. However, 18F-fluciclovine is not specific for prostate cancer. Nonprostatic malignancies and benign conditions can also demonstrate uptake. This information combined with the knowledge about common patterns of prostate cancer recurrence helps guide appropriate management. We present an 87-year-old man with biochemical recurrence for prostate cancer but found to have a urinary bladder wall mass on 18F-fluciclovine PET/CT with moderate avidity. Biopsy revealed papillary urothelial carcinoma.

show abstract

Bladder wall recurrence of prostate cancer after high-dose-rate brachytherapy

Cited by 5 publications

References 13 publications

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

Revisiting Prostate Cancer Recurrence with PSMA PET: Atlas of Typical and Atypical Patterns of Spread

Perineal recurrence of prostate cancer post-brachytherapy

Papillary Urothelial Carcinoma of Urinary Bladder Identified on 18F-Fluciclovine PET/CT

Contact Info

Product

Resources

About